- Cipla has priced its generic version of remdesivir, Cipremi at Rs 4000 ($53.34/ 100ml) vial, making it the lowest priced COVID-19 therapy across the globe, when compared with Hetero’s Covifor which is sold at Rs 5,400/ 100 mg vial and Mylan’s Desrem is priced at Rs 4,800.
- The company focuses on supplying over 80,000 vials within the first month. To ensure equitable distribution, Cipremi will be available via government and hospital channels
- On Jul 07, 2020, Sovereign Pharma, which is manufacturing and packaging the therapy for Cipla had dispatched the first batch. Gilead has priced the original version at $390/ 100 mg vial for developed countries while signed a license agreement with generic producers to make the treatment widely available
Click here to read full press release/ article | Ref: Reuters | Image: Express Pharma